Randomized phase 2 trial: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19
29 Oct, 2020 | 09:16h | UTCAudio Interview: A New Monoclonal Antibody for Covid-19 – New England Journal of Medicine
Commentaries on Twitter
BLAZE-1? – outpatient trial of LY-Cov555, mAb recently dropped from ACTIV-3 inpatient trial
Only 1 of the 3 mAb dosages (middle one ?♂️) ⬇️ VL by d11
mAb assoc with modest ⬇️ in healthcare visits (1.6% vs 6.3% for placebo)
? Far from a game changerhttps://t.co/zZMGlodaaF pic.twitter.com/ofs1UgN1ZA
— Ilan Schwartz MD PhD (@GermHunterMD) October 28, 2020
Phase 2 Lilly #SARSCoV2 monoclonal antibody outpatient trial just published @NEJM
The lack of a dose response for viral load reduction +modest effects on symptoms do not make this look like a potent intervention https://t.co/oyRG8fUNHf pic.twitter.com/uobuCIznmD— Eric Topol (@EricTopol) October 28, 2020